Mycolic Acid
Mycolic acids are extraordinarily long-chain, branched α-alkyl β-hydroxy fatty acids forming the waxy outer mycomembrane of Mycobacterium tuberculosis and related actinomycetes, conferring acid-fastness and intrinsic antibiotic impermeability.
Mycolic acids are structurally distinctive, high-molecular-weight α-alkyl, β-hydroxy long-chain fatty acids (typically 60 to 90 carbons long in Mycobacterium, shorter in Corynebacterium and Nocardia) that form the defining hydrophobic barrier of the mycobacterial cell envelope. Covalently esterified to the underlying arabinogalactan–peptidoglycan core as well as packaged into non-covalent outer-leaflet glycolipids such as trehalose dimycolate (cord factor), mycolic acids assemble into a dense, waxy, low-fluidity mycomembrane that accounts for the acid-fast staining property of Mycobacterium tuberculosis, its extreme desiccation tolerance, and its high intrinsic resistance to hydrophilic antibiotics and macrophage oxidative killing (Barry et al., 1998; Marrakchi et al., 2014).
Molecular Architecture and Structural Subclasses
Every mycolic acid shares a conserved mycolic motif—a β-hydroxy carboxylic acid bearing a saturated α-alkyl side chain (C₂₂–C₂₆)—joined to a long meromycolate chain (C₄₀–C₆₀) that defines species-specific permeability and virulence (Marrakchi et al., 2014). In Mycobacterium tuberculosis, three major meromycolate classes predominate:
- α-Mycolates: Contain two cis-cyclopropane rings along the meromycolate backbone and lack oxygen functional groups, forming the tightest, most impermeable lipid packing.
- Methoxymycolates and Ketomycolates: Carry oxygenated methoxy or keto functional groups alongside cis- or trans-cyclopropane rings, modulating mycomembrane fluidity, macrophage phagosome-maturation arrest, and biofilm formation.
Biosynthesis via FAS-I, FAS-II, and Polyketide Condensing Enzymes
Mycolic acid assembly requires a coordinated enzymatic cascade absent from mammalian cells, making it a premier target for anti-tuberculosis chemotherapy (Takayama et al., 2005):
- FAS-I De Novo Synthesis: A single multifunctional eukaryotic-like fatty acid synthase I (FAS-I) generates C₁₆–C₂₆ acyl-CoAs, supplying both the α-branch and primer substrates for meromycolate elongation.
- FAS-II Elongation Cycle: A dissociated bacterial FAS-II complex—featuring the enoyl-ACP reductase InhA and β-ketoacyl-ACP synthases KasA/KasB—iteratively extends primers up to C₅₀–C₆₀ meromycolate chains, which are subsequently modified by S-adenosylmethionine-dependent cyclopropane synthases (PcaA, MmaA1–4).
- Pks13 Claisen Condensation & MmpL3 Export: Polyketide synthase Pks13 condenses the activated α-branch and meromycolate chain, after which trehalose monomycolate (TMM) is flipped across the plasma membrane by the essential RND-like transporter MmpL3 and transferred onto arabinogalactan or another TMM molecule by the Antigen 85 (Ag85A/B/C) mycolyltransferase complex.
Clinical Pharmacology and Tuberculosis Drug Targets
Because human cells lack FAS-II and mycomembranes, frontline and next-generation tuberculosis drugs selectively target mycolic acid biosynthesis (Takayama et al., 2005; Marrakchi et al., 2014). Isoniazid (INH)—activated by the mycobacterial catalase-peroxidase KatG—and ethionamide form covalent NAD adducts that potently inhibit InhA, collapsing mycomembrane integrity and triggering rapid bacterial lysis. Newer clinical candidates, including SQ109 and indolecarboxamides, block MmpL3-mediated trehalose monomycolate export, offering potent activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains.
Structural Diversity Across Mycobacterial Classes
Mycolic acids are not uniform molecules; mycobacteria synthesize multiple structurally distinct subclasses whose ratios shift in response to host stress and growth phase. In Mycobacterium tuberculosis, three major families predominate: α-mycolic acids (the most abundant class, containing two cis-cyclopropane rings along the meromycolate chain), methoxymycolic acids, and ketomycolic acids (oxygenated classes carrying a single cyclopropane ring plus a methoxy or keto functional group). The enzymes PcaA, MmaA2, and CmaA2 install these cyclopropane rings during late-stage maturation, tightening lipid packing within the mycomembrane. Mutants lacking oxygenated mycolic acids or specific cyclopropane rings exhibit marked attenuation in macrophage survival assays and fail to form normal corded serpentine colonies, demonstrating that fine chemical tailoring of the meromycolate chain modulates both outer-membrane fluidity and virulence.
Diagnostic Acid-Fast Staining and Cord Factor Activity
The extraordinary hydrophobicity and thickness of the mycolic acid layer underpin the classic Ziehl–Neelsen acid-fast stain used in clinical microbiology since the nineteenth century. Carbolfuchsin dye driven into the mycobacterial envelope by heat resists decolorization by acid–alcohol washes because mycolates trap the dye complex inside the waxy arabinogalactan-bound barrier. In addition, trehalose 6,6′-dimycolate (TDM), historically termed cord factor, acts as a potent glycolipid immunomodulator: TDM binds the macrophage C-type lectin receptor Mincle (CLEC4E), driving granuloma formation, TNF-α secretion, and caseous necrosis characteristic of pulmonary tuberculosis pathology. Understanding how mycolic acid chain length, cyclopropanation, and trehalose esterification jointly govern envelope permeability continues to guide structure-based design of next-generation antitubercular drugs.
Frequently Asked Questions
How does isoniazid selectively target mycobacteria without harming human cells?
Isoniazid is a prodrug activated by the mycobacterial catalase-peroxidase KatG into an isonicotinoyl radical that forms a covalent adduct with NAD+. This adduct potently inhibits the enoyl-ACP reductase InhA of the FAS-II mycolic acid elongation pathway, a biosynthetic enzyme absent in human cells, halting mycomembrane assembly and causing mycobacterial cell death.
References
- Marrakchi, H., Lanéelle, M.-A., & Daffé, M. (2014). Mycolic acids: Structures, biosynthesis, and beyond. Chemistry & Biology, 21(1), 67–85. https://doi.org/10.1016/j.chembiol.2013.11.011
- Barry, C. E., III, Lee, R. E., Mdluli, K., Sampson, A. E., Schroeder, B. G., Slayden, R. A., & Yuan, Y. (1998). Mycolic acids: Structure, biosynthesis and physiological functions. Progress in Lipid Research, 37(2–3), 143–179. https://doi.org/10.1016/S0163-7827(98)00008-300008-3)
- Takayama, K., Wang, C., & Besra, G. S. (2005). Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clinical Microbiology Reviews, 18(1), 81–101. https://doi.org/10.1128/CMR.18.1.81-101.2005